STAT+: CVS Health to split, reversing years of deal-making to combine pharmacies and insurance

CVS is splitting its conglomerate into CVS Health and CVS Pharmacy. Both companies will remain publicly traded and keep CVS in their names. The move separates the pharmacy chain from the businesses that manage drug benefits, provide insurance, and deliver some medical care. The article does not describe a timetable or detailed legal structure for the separation.

CVS Health will include Caremark, the pharmacy benefit manager; Aetna, the health insurer; the specialty pharmacy; and companies providing primary care and home visits to older adults. CVS Pharmacy will be the separate company for CVS’s pharmacy business. This creates a major dividing line between retail pharmacy operations and the broader health-care businesses.

The split does not fully untangle CVS’s drug-related operations. Specialty pharmacy remains inside CVS Health alongside Caremark and Aetna. That means expensive medicines will still connect a dispensing business with a large benefit manager and insurer, preserving the conflict critics focus on. Investors and regulators will therefore watch how the new companies interact.

CVS is influential because it operates across several powerful parts of U.S. health care. The article describes CVS as one of the country’s largest health-care conglomerates. Its businesses include a national pharmacy operation, Caremark, a major pharmacy benefit manager, Aetna, a health insurer, and specialty pharmacy. Together, those positions can affect how medicines are covered, dispensed, and paid for.

The key mechanism is vertical integration. A pharmacy benefit manager can shape formularies, pharmacy networks, and reimbursement rules. An insurer determines coverage and pays claims under health plans. Pharmacies dispense medicines directly to patients. When one corporate group operates in all three areas, decisions in one business can influence the others.

The article does not provide market share, revenue, enrollment, store counts, or prescription volume. So its scale is best understood qualitatively, not numerically. The separation changes corporate ownership, but CVS Health will still combine Caremark, Aetna, specialty pharmacy, and care businesses. That leaves its system-wide influence substantial.

The split changes who owns and reports the businesses, not necessarily how patients fill prescriptions or use insurance on day one. CVS Pharmacy will stand apart as a public company. CVS Health will contain Aetna, Caremark, specialty pharmacy, primary care, and home visits for older adults. The article does not announce new prices, networks, benefits, or operating rules.

For patients and pharmacies, the practical effects depend on future contracts and policies. Caremark could still manage prescription benefits for Aetna and other plans. Specialty pharmacy will remain in the same company as Caremark and Aetna. For insurers, the separation may make dealings with CVS’s retail pharmacies more visibly arm’s-length, but the article does not promise that outcome.

Investors will receive separate financial reporting and may value the companies differently. The split could clarify performance and expose conflicts, yet the central concern remains. CVS Health will still link drug dispensing, benefit management, and insurance. Any meaningful patient or pharmacy impact will depend on decisions made after separation.

The source gives no historical explanation for CVS’s decades of dealmaking. It only describes the result: a large conglomerate containing pharmacies, a pharmacy benefit manager, an insurer, specialty pharmacy, primary care, and home visits. Any account of the original strategy therefore comes from established industry context rather than this article.

Companies vertically integrate when they want influence over several linked steps. An insurer pays for care, a pharmacy benefit manager organizes drug coverage, and pharmacies dispense medicines. Combining them can support shared data, coordinated services, negotiating leverage, and internal referrals. It can also let a company capture revenue in more than one part of a transaction.

Those advantages come with scrutiny. Critics may question whether an integrated company steers business toward its own units or makes pricing difficult to understand. CVS’s decision to split shows that conglomeration can later become a liability, or at least something investors want separated. The article does not identify the specific deals or motives that built CVS.

A pharmacy benefit manager is an intermediary that administers prescription-drug benefits for health plans. A PBM commonly builds pharmacy networks, processes claims, manages formularies, negotiates manufacturer rebates, and sets or influences reimbursement terms. Its purpose is to organize access and payment for medicines, although its pricing practices can be difficult to see.

Caremark performs that coordinating role within CVS Health. It can work with insurers such as Aetna to design covered-drug rules, negotiate with manufacturers, connect patients to participating pharmacies, and process prescriptions at the point of sale. Specialty pharmacy adds another link because it dispenses costly or complex medicines. The article identifies Caremark as CVS’s PBM but does not spell out its individual contracts.

This arrangement matters because Caremark remains alongside Aetna and specialty pharmacy after the split. A single corporate group can therefore influence coverage, payment, and dispensing around the same prescription. The article highlights that continuing connection as a point of contention, especially when expensive drugs are involved.

Critics worry about incentives when one company operates the benefit manager, insurer, and pharmacy dispensing a drug. Each unit can affect a different part of the transaction. The insurer determines coverage, the PBM manages benefits and pharmacy payments, and the specialty pharmacy dispenses expensive medicines. The article says this combination has drawn criticism over excessive prescription-drug profits.

For example, CVS Health will retain Caremark, Aetna, and its specialty pharmacy. A costly medicine dispensed by the specialty pharmacy can therefore remain connected to the PBM that manages benefits and the insurer that covers the treatment. In theory, internal links may improve coordination. Critics fear they could also encourage steering, opaque pricing, or retaining value within the corporate group.

The split does not remove that concern. CVS Pharmacy will become separate, but the specialty pharmacy stays with Caremark and Aetna. The article offers no evidence that CVS violated a rule or overcharged a particular patient. It identifies a structural conflict that regulators, customers, and investors may continue examining.

A prescription typically involves several financial roles. The drug manufacturer earns revenue from selling the medicine. A pharmacy buys or receives the drug and earns a dispensing payment plus any allowed margin. The insurer collects premiums or public program funding, then pays covered claims. A PBM administers the benefit and may receive administrative fees or other compensation under its contract.

The mechanism varies by contract. A PBM may negotiate a lower price or rebate with a manufacturer, create a formulary, process the claim, and reimburse a participating pharmacy. The patient may pay a copayment, coinsurance, or deductible. The insurer pays the rest of the covered amount, while the pharmacy and manufacturer receive payments through their agreements. Exact flows are not stated in the article.

Ultimately, money comes from patients, employers, taxpayers, or government programs, depending on coverage. Premiums and taxes fund insurance pools; patient cost sharing pays at the counter. The article focuses on CVS’s overlapping roles and critics’ profit concerns, not on a specific prescription’s price or margins.